LOX and keratoconus: Extrapolating from these data, one can plausibly envision KC-directed approaches—such as siRNA or antisense constructs targeting matrix-degrading enzymes, or oligonucleotides enhancing protective factors like LOX or antioxidant pathways—but no RNA-based therapy has yet been tested clinically in keratoconus, and target selection, delivery, off-target effects, and long-term safety all remain major challenges.